You are here: Industry Insights > Orgenesis

News List

Orgenesis Announces Collaboration Agreement with Tel Aviv Sourasky Medical Center to Advance Point-of-Care Development and Commercialization of Cell and Gene and Therapies FirstWordPharma
November 16, 2021
Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapies, has entered into a collaboration agreement...
Orgenesis to Acquire Koglio Therapeutics contractpharma
October 09, 2020
Will accelerate the commercialization of Koligo’s KYSLECEL, a personalized islet cell therapy available in the U.S. for chronic and recurrent acute pancreatitis.
Orgenesis to Collaborate with Educell to Conduct Clinical Validation of Cell Therapies Using Orgenesis’ Proprietary POCare Technologies for the Generation and Expansion of T-Cells PharmaSources.com
August 12, 2020
GERMANTOWN, MD – July 14, 2020 – Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a pioneering global biotech company committed to accelerating commercialization and transforming the delivery of cell and gene therapies (CGTs).
Orgenesis Enters Collaboration Agreement with Educell contractpharma
July 15, 2020
Orgenesis Inc., a global biotech company committed to accelerating commercialization and transforming the delivery of cell and gene therapies (CGTs), has entered into a Collaboration Agreement with Educell Ltd., a European cell therapy company.
Orgenesis to Acquire Tamir Bio Assets contractpharma
April 15, 2020
Aims to combine ranpirnase antiviral platform with Bioxome technology for enhanced payload delivery directly to cells.
Orgenesis, ExcellaBio Enter Cell Therapy Tie-up contractpharma
April 18, 2019
Orgenesis, a developer, manufacturer and service provider of advanced cell therapies, has entered into a collaboration and licensing agreement with ...
Orgenesis Enters Drug Devt. Collaboration with Ben-Gurion Univ. contractpharma
August 24, 2018
Orgenesis, a manufacturer, service provider and developer of advanced cell therapies, along with BGN Technologies and the National Institute for Biotechnology in the Negev (NIBN)......